New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
07:28 EDTSHPGShire enters licensing and collaboration agreement with ArmaGen
Shire and ArmaGen, a US privately held biotechnology company, announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy for the potential treatment of both the central nervous system and somatic manifestations in patients with Hunter syndrome. Shire will obtain worldwide commercialization rights for AGT-182 in exchange for payments of approximately $225M to ArmaGen, including an initial upfront payment of $15M in cash and equity, an additional equity investment, R&D funding, development milestones and sales milestones, in addition to royalty payments. ArmaGen will be responsible for conducting and completing the Phase I/II study which it expects to initiate before the end of 2014, after which point Shire will be responsible for further clinical development, including Phase III trials, and commercialization.
News For SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
17:28 EDTSHPGShire partner Shionogi submits NDA in Japan for ADHD treatment for children
Subscribe for More Information
10:02 EDTSHPGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aralez (ARLZ) initiated with a Buy at Guggenheim... Atlassian (TEAM) initiated with a Neutral at Baird... CareDx (CDNA) initiated with a Buy at Janney Capital... Denison Mines (DNN) initiated with a Buy at Roth Capital... Deutsche Boerse (DBOEY) initiated with a Neutral at Exane BNP Paribas... Instructure (INST) initiated with an Outperform at Oppenheimer... Kirkland's (KIRK) initiated with a Buy at B. Riley... Mesa Labs (MLAB) initiated with a Buy at Janney Capital... Natural Grocers (NGVC) initiated with a Hold at Deutsche Bank... Nordex (NRDXF) initiated with an Overweight at Barclays... Old Line Bancshares (OLBK) initiated with a Market Perform at Keefe Bruyette... Shire (SHPG) initiated with a Neutral at Guggenheim... T2 Biosystems (TTOO) initiated with a Buy at Cantor... iRobot (IRBT) initiated with a Buy at Chardan.
09:19 EDTSHPGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Akamai (AKAM), up 16.5%... Prospect Capital (PSEC), up 10.7%... Panera Bread (PNRA), up 2%. ALSO HIGHER: Deutsche Bank (DB), up 6.1% after the Financial Times reported that the company is considering a multibillion bond buyback... Fitbit (FIT), up 3.7% after Marc Benioff reported a 5% stake in the company... FireEye (FEYE), up 3.9% after being upgraded to Buy from Neutral at BTIG... Shire (SHPG), up 1.7% after being upgraded to Outperform from Sector Perform at RBC Capital. DOWN AFTER EARNINGS: Time Warner (TWX), down 7.6%... Disney (DIS), down 5.1%... SolarCity (SCTY), down 27.8%. ALSO LOWER: CTI BioPharma (CTIC), down 38% after the FDA placed pacritinib IND on full clinical hold... Mast Therapeutics (MSTX), down 40.1% after 29.1M share Spot Unit offering priced at $0.275.
08:25 EDTSHPGShire upgraded on valuation at RBC Capital
As noted earlier, RBC Capital upgraded Shire to Outperform from Sector Perform. The firm believes that the recent decline in the stock more than accounts for any competitive risks facing the company's Baxalta drug. Target $240.
07:19 EDTSHPGShire says David Kappler to step down as deputy chairman
Subscribe for More Information
06:28 EDTSHPGShire upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information
February 9, 2016
16:14 EDTSHPGShire initiated with a Neutral at Guggenheim
09:56 EDTSHPGIntercept higher following report of vague takeover chatter
Shares of Intercept Pharmaceuticals (ICPT) are moving after United Kingdom blog Proactive Investors discussed "reheated rumours" of a takeover. "Vague talk" has Intercept teaming up with CenterView Partners to advise on a sale, the blog states. It mentions AstraZeneca (AZN) as a possible suitor now that Shire (SHPG) has reached an agreement to acquire Baxalta (BXLT). Shares of Intercept, which is developing treatments for chronic liver diseases, are up 4% to $97.39 in early trading.
February 4, 2016
16:00 EDTSHPGShire's NDA for lifitegrast for dry eye resubmssion acknowledged by FDA
Shire announced that the FDA has acknowledged receipt of the resubmission of the New Drug Application for lifitegrast for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter received from the FDA on October 16, 2015 that requested an additional clinical study and more information related to product quality. The FDA determined that the submission is a complete response and has assigned a 6-month review period for the NDA and a Prescription Drug User Fee Act goal date of July 22.
February 3, 2016
08:07 EDTSHPGMedgenics names Brian Piper to succeed John Leaman as CFO
Subscribe for More Information
February 2, 2016
09:46 EDTSHPGIntercept rumored to draw interest from many suitors, Daily Mail says
Subscribe for More Information
January 28, 2016
10:05 EDTSHPGHigh option volume stocks
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use